Retka mesta metastatskog karcinoma bubrežnog parenhima

  • Novak Milović Department of Urology, Military Medical Academy, Belgrade, Serbia, Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
  • Miodrag Lazić Department of Urology, Medical Center „Dr Dragiša Mišović-Dedinje“, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
  • Predrag Aleksić Department of Urology, Military Medical Academy, Belgrade, Serbia, Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
  • Dragan Radovanović Department of Surgery, Medical Center „Dr Dragiša Mišović-Dedinje“, Belgrade, Serbia
  • Vladimir Bančević Department of Urology, Military Medical Academy, Belgrade, Serbia, Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
  • Slaviša Savić Department of Urology, Medical Center „Dr Dragiša Mišović-Dedinje“, Belgrade, Serbia;
  • Dušica Stamenković Department of Anesthesia and Intensive Care, Military Medical Academy, Belgrade, Serbia
  • Dušan Spasić Department of Surgery, Medical Center „Dr Dragiša Mišović-Dedinje“, Belgrade, Serbia
  • Branko Košević Department of Urology, Military Medical Academy, Belgrade, Serbia
  • Mirko Jovanovic Military Medical Academy, Urology Clinic
  • Dragoljub Perović Clinic of Urology and Nephrology, Clinical Center of Montenegro, Podgorica, Montenegro
Ključne reči: carcinoma, renal cell||, ||karcinomi bubrežnog parenhima, neoplasm metastasis||, ||neoplazme, metastaze, urologic surgical procedures||, ||hirurgija, urološka, procedure, treatment outcome||, ||lečenje, ishod,

Sažetak


Uvod. Tumori bubrežnog parenhima (renal cell carcinoma – RCC) čine 3% maligniteta odraslih osoba. Najčešća lokalizacija metastaza RCC je u plućima, limfnim žlezdama, jetri i kostima, ali se u retkim slučajevima nalaze i u drugim organima. Prikaz bolesnika. Dve godine nakon radikalne levostrane nefrektomije zbog RCC, 63-godišnjem bolesniku je učinjena limfadenektomija zbog metastaze RCC u paraaortalnu limfnu žlezdu. Deset meseci kasnije, učinjena je levostrana hemikolektomija zbog metstaze RCC u rektosigmoidni kolon. Kod drugog bolesnika, starog 37 godina, dve godine nakon levostrane radikalne nefrektomije zbog RCC, urađena je parcijalna desnostrana nefrektomija. U daljem periodu praćenja bolesnika, urađeno je više hirurških zahvata u cilju uklanjanja metastaza iz različitih organa: metastazektomija pluća, resekcija tankih creva i cekuma, i desnostrana orhiektomija. Dve godine nakon primarnog hirurškog zahvata došlo je do letalnog ishoda usled širenja bolesti na koštani sistem i mozak. Treći bolesnik, star 35 godina, nakon desnostrane nefrektomije zbog metastatskih promena RCC u limfnim žlezdama prošao je kroz limfadenektomije 6, 12 i 24 meseca nakon primarne operacije. Kod istog bolesnika četiri godine nakon primarne operacije, učinjena je desnostrana hemikolektomija zbog metastatske promene RCC u cekumu. Zaključak. Praćenje bolesnika nakon nefrektomije zbog RCC uz korišćenje metoda snimanja u određenim vremenskim intervalima doprinosi pravovremenom otkrivanju metastaza. Primena odgovarajućeg hirurškog zahvata u ranoj fazi poboljšava produžavanja i popravlja kvalitet života bolesnik.

Biografija autora

Novak Milović, Department of Urology, Military Medical Academy, Belgrade, Serbia, Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Dept of Urology

Reference

Garcia JA, Cowey CL, Godley PA. Renal cell carcinoma. Curr Opin Oncol 2009; 21(39): 266–71.

Cooperberg MR, Mallin K, Ritchey J, Villata JD, Carol PR, Kane CJ. Decreasing size at diagnosis of stage 1 renal cell carcinoma: analysis from the National Cancer Data Base, 1993 to 2004. J Urol 2008; 179(6): 2131−5.

Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173(6): 1853−62.

Ljungberg B. Prognostic factors in renal cell carcinoma. Scand J Surg 2004; 93(2): 118−25.

Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, et al. EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010; 58(3): 398−406.

Ruutu M, Bono P, Taari K. Resection of renal cell carcer me-tastases:Where do we stand in 2008? Eur Urol Suppl 2008; 7(5): 436−42.

Blom JH, van Poppel H, Marechal JM, Jacqmin D, Sylvester R, Schröder FH, et al. Radical nephrectomy with and without lymph node dissection: preliminary results of the EORTC randomized phase III protocol 30881. EORTC Genitourinary Group. Eur Urol 1999; 36(6): 570−5.

Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, et al. Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol 2003; 169(6): 2076−83.

Kavolius JP, Mastorakos DP, Pavlovich C Russo P, Burt ME, Brady MS. Resection of metastatic renal cell carcinoma. J Clin Oncol 1998; 16(6): 2261−6.

Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Im-munotherapy for advanced renal cell cancer. Cochrane Data-base Syst Rev 2005; (1): CD001425.

Jung ST, Ghert MA, Harrelson JM, Scully SP. Treatment of osse-ous metastases in patients with renal cell carcinoma. Clin Or-thop Relat Res 2003; (409): 223−31.

Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, et al. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 2007; 89(8): 1794−801.

Senadhi V, Jani N, Erlich R. Metastatic Renal Cell Cancer and a Gastric Mass: An Unusual Finding. Case Rep Gastroenterol 2010; 4(3): 421−8.

Wroński M, Arbit E, Russo P, Galicich JH. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996; 47(2): 187−93.

Sheehan JP, Sun MH, Kondziolka D, Flickinger J, Lunsford LD. Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influ-encing survival and local tumor control. J Neurosurg 2003; 98(2): 342−9.

Objavljeno
2017/01/20
Broj časopisa
Rubrika
Prikaz bolesnika